N-Acetylcysteine Shows Promise for Brain Injury Recovery and Parkinson's Disease

N-acetylcysteine (NAC), a glutathione precursor with antioxidant properties, has emerged as a potential neuroprotective agent across multiple brain disorders. This comprehensive systematic review examined clinical evidence for NAC in seven neurological conditions, revealing promising but fragmented results.

Researchers analyzed 23 studies spanning traumatic brain injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, and migraine. The strongest evidence emerged for acute mild traumatic brain injury, where early NAC administration (within 24 hours) significantly improved symptom resolution compared to placebo, with an 86% chance of complete recovery versus 42% for placebo.

In Parkinson's disease, combined intravenous and oral NAC treatment improved dopamine transporter binding, suggesting potential disease-modifying effects. For Alzheimer's disease, nutraceutical formulations containing NAC showed trends toward cognitive stabilization, though results were mixed across studies.

The review revealed significant methodological limitations: most studies had high or serious risk of bias, and only eight of 23 studies actually measured oxidative stress biomarkers despite NAC's primary mechanism being antioxidant activity. Sample sizes were generally small, ranging from 6 to 110 participants, and treatment protocols varied widely in dose, duration, and administration route.

Despite these limitations, NAC demonstrated a consistently favorable safety profile across all neurological conditions studied. The encouraging signals identified, particularly for brain injury and Parkinson's disease, warrant larger, well-designed randomized controlled trials with standardized biomarker assessment to definitively establish NAC's therapeutic potential in neurological disorders.